This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
by Zacks Equity Research
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Ironwood/Allergan Settle Linzess Patent Litigation With Mylan
by Zacks Equity Research
Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.
Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.
Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -171.43% and -28.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Allergan (AGN) beats third-quarter estimates for earnings and sales and raises its full-year guidance for both the metrics. Botox remains the primary sales driver.
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Pharmaceuticals (IRWD) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.
Ironwood Stock Up, Heart Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
Why Is Ironwood (IRWD) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood's Linzess Gets Approval in Japan for New Indication
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Ironwood Pharmaceuticals (IRWD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -47.37% and -9.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Begins New Phase III Study to Expand Linzess Label
by Zacks Equity Research
Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.
Ironwood Initiates Phase III Studies on Reflux Candidate
by Zacks Equity Research
Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.
Ironwood Pharmaceuticals (IRWD) Down 10.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.
Ironwood Succeeds in Diabetic Hypertension Phase II Study
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.
Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.
Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up
by Zacks Equity Research
Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.
Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood Pharma's Combination Gout Drug Gets FDA Approval
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.